Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Εμφάνιση άλλων εκδόσεων (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2014

Παρόμοια τεκμήρια

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
ανά: Ruiz Garcia, V, κ.ά.
Έκδοση: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
ανά: Galina Viktorovna Lukina, κ.ά.
Έκδοση: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
ανά: M Connock, κ.ά.
Έκδοση: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
ανά: Vera Nikolayevna Amirdjanova, κ.ά.
Έκδοση: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
ανά: Evgeniy L'vovich Nasonov, κ.ά.
Έκδοση: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
ανά: Emna Hannech, κ.ά.
Έκδοση: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
ανά: Dmitry Evgenyevich Karateev, κ.ά.
Έκδοση: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
ανά: T. V. Korotaeva, κ.ά.
Έκδοση: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
ανά: Maria Majdan, κ.ά.
Έκδοση: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
ανά: Mariusz Korkosz
Έκδοση: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
ανά: Smolen, JS, κ.ά.
Έκδοση: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
ανά: Purcaru, O, κ.ά.
Έκδοση: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
ανά: J Rosa, κ.ά.
Έκδοση: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
ανά: Sh. F. Erdes
Έκδοση: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
ανά: Andrea Bassi, κ.ά.
Έκδοση: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
ανά: José Alexandre Mendonça, κ.ά.
Έκδοση: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
ανά: Stéphane Paul, κ.ά.
Έκδοση: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
ανά: Mehmet Baysal, κ.ά.
Έκδοση: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
ανά: Lindsey J. Wanberg, κ.ά.
Έκδοση: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
ανά: Tanaka, Y, κ.ά.
Έκδοση: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
ανά: Karine Arnoldovna Lytkina, κ.ά.
Έκδοση: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
ανά: Karine Arnoldovna Lytkina, κ.ά.
Έκδοση: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
ανά: Ian R White, κ.ά.
Έκδοση: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
ανά: Ian R. White, κ.ά.
Έκδοση: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
ανά: Vivian P. Bykerk, κ.ά.
Έκδοση: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
ανά: Glatt, S, κ.ά.
Έκδοση: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
ανά: Clóvis Dervil Appratto Cardoso Júnior, κ.ά.
Έκδοση: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
ανά: I.L. Khalif, κ.ά.
Έκδοση: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
ανά: Ranatunga S, κ.ά.
Έκδοση: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
ανά: Piotr Wiland, κ.ά.
Έκδοση: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
ανά: Acosta-Felquer ML, κ.ά.
Έκδοση: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
ανά: P. I. Novikov, κ.ά.
Έκδοση: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
ανά: Hazes, J, κ.ά.
Έκδοση: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
ανά: A. Spadaro, κ.ά.
Έκδοση: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
ανά: Wojciech Blonski, κ.ά.
Έκδοση: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
ανά: O V Knyazev, κ.ά.
Έκδοση: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
ανά: Yael Sharon, κ.ά.
Έκδοση: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
ανά: R. Talotta, κ.ά.
Έκδοση: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
ανά: Syuichi Koarada, κ.ά.
Έκδοση: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
ανά: Jeffrey R. Curtis, κ.ά.
Έκδοση: (2017-12-01)